|
|
Biotechnology Growth StrategiesPublished by: Datamonitor Published: Feb. 15, 2002 - 316 Pages Table of ContentsEXECUTIVE SUMMARY Action points Intra-biotech alliances will drive future product commercialization independent of pharmaceutical partners, enabling biotechnology companies to retain a larger share of revenues Integration costs and the inflexibility of M&A timing make in-licensing a more cost-effective long term growth strategy for fully integrated biotechnology companies Development stage companies with target rich pipelines should continue to out-license products, only embarking upon marketing when sufficient internal capabilities allow a self-marketing strategy Integrating target discovery capabilities into technology service companies' growth strategies protects against mimicry and will drive progress towards becoming development stage companies Greater competition between pharmaceutical companies to become parnter of choice requires offering biotechnology companies access to drug development capabilities THE BIOTECHNOLOGY MARKET Changing biotechnology market Highly competetive market environment Evolving demands and relationship with pharmaceutical companies Strong aim for independence Benchmarking biotechnology company performance Market capitalization: the definitive success metric Market capitalization of profiled companies Biotechnology company growth strategies Cost containment Income Perception Product potential Summary GROWTH STRATEGIES OF FULLY INTEGRATED BIOTECHNOLOGY COMPANIES Key growth strategies of fully integrated biotechnology companies Implementation of integrated biotechnology company growth strategies Amgen Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Genentech Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Serono Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Immunex Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Genzyme Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary GROWTH STRATEGIES OF DEVELOPING BIOTECHNOLOGY COMPANIES Key growth strategies of developing biotechnology companies Implementation of developing biotechnology company growth strategies IDEC Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Millennium Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary ImClone Systems Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Human Genome Sciences Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary ICOS Pharmaceuticals Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary GROWTH STRATEGIES OF CO-DEVELOPMENT BIOTECHNOLOGY COMPANIES Key growth strategies of co-developing biotechnology companies Implementation of co-developing biotechnology company growth strategies Abgenix Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth Summary Medarex Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Curagen Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary Cambridge Antibody Technology Financial summary Growth strategy to date Resistors of growth strategy Future growth strategy Summary Exelixis Financial summary Growth strategy to date Resistors of growth Future growth Summary GROWTH STRATEGIES OF TECHNOLOGY PLATFORM COMPANIES Key growth strategies of technology platform biotechnology companies Implementation of technology company growth strategies Affymetrix Financial summary, 2000-1999 Growth strategy to date Resistors of the growth strategy Future growth strategy Summary Celera Genomics Financial summary Growth strategy to date Resistors of the growth strategy Future growth strategy Summary Incyte Genomics Financial summary, 2000-1999 Growth strategy to date Resistors of the growth strategy Future growth strategy Summary Lexicon Genetics Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary GeneLogic Financial summary, 2000-1999 Growth strategy to date Resistors of growth strategy Future growth strategy Summary FUTURE BIOTECHNOLOGY MARKET Introduction Significant trends in the biopharmaceutical market Which external market factors will be significant over the next ten years? Changing regulatory and approval policies Development of different financial ‘windows’ Changing interest in ‘hot-topic’ Evolving investor demands Changing pressure from globalizaiton Uptake of pharmacogenomics Willingness to accept risk and launch products Pharmaceutical companies moving along the value chain Summary of scenarios impacting on biopharmaceutical growth strategies Changing integrated biotechnology company growth strategies Changing regulatory and approval policies Changes in the financial window Changes in the ‘hot-topic’ focus Changing investor demands Changing pressure from globalization Pharmacogenomic penetration Willingess to accept risk and launch products Changes in the pharmaceutical value chain Changing developing and co-developing biotechnology company growth strategies Changing regulatory and approval policies Changes in the financial window Changes in the ‘hot-topic’ Moving investor demands Changing pressure from globalizaiton Pharmacogenomic penetration Willingness to accept risk and launch products Changes in the pharmaceutical value chain Changing technology platform company growth strategies Changing regulatory and approval policies Changes in the financial window Changes in the ‘hot-topic’ Changing investor demands Globalization pressure Pharmacogenomic penetration Risk strategy Changes in the pharmaceutical value chain Summary - the need to evolve Impact on pharmaceutical companies by biotechnology company responses to changing market factors Change in the balance of power Increasing cost of alliances Achieving partner of choice status Multiple technology access agreements Summary APPENDIX Supplementary data Ethical Revenues Biotechnology Market Capitalization Exchange rates Related reading from Datamonitor Healthcare Datamonitor’s Strategy team Jennifer Coe, Strategy Director Nick Bennett, Senior Managing Analyst © Datamonitor 2002. All Rights Reserved. Abstract'Biotechnology Company Growth Strategies: Intra-biotech Collaborations Bring Independence From Pharma One Step Closer' analyzes changes in biotechnology company growth strategies. It presents a primary research-based analysis of the long-term growth strategies of biotechnology companies and the tactics employed to achieve growth. It draws upon 20 in-depth company case studies to identify the characteristics that define success at each stage of the biotechnology growth curve (fully integrated, developing, co-developing and technology platform companies). Each chapter benchmarks financial performance, details major collaborations, discusses the most successful growth strategies and predicts future growth plans. It also forecasts the impact of eight market factors on the biotechnology market. Each factor is illustrated with reference to three scenarios, that project the impact of a positive, negative or stationary outcome. This provides the framework for strategic recommendations to improve biotechnology company growth prospects in the face of changing biotechnology market conditions, and the impact of this changing environment on the pharmaceutical sector.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||